John Bell
Ottawa University
H-index: 89
North America-United States
Top articles of John Bell
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T … | bioRxiv | Edward Armstrong Matthew KL Chiu Shane Foo Lizzie Appleton Pablo Nenclares | 2024 |
Modified orthopoxvirus vectors | 2023/10/31 | ||
SARS-CoV-2 lineage assignments using phylogenetic placement/UShER are superior to pangoLEARN machine-learning method | Virus Evolution | Adriano de Bernardi Schneider Michelle Su Angie S Hinrichs Jade Wang Helly Amin | 2024/1/1 |
Optimizing oncolytic virus design: a “Swiss army knife” approach to create a systemically delivered therapeutic | Signal Transduction and Targeted Therapy | Carolina S Ilkow John Cameron Bell | 2024/4/2 |
Abstract B054: Defective STING signaling in low-grade serous ovarian cancer: an opportunity for oncolytic viruses therapy | Cancer Research | Almira Zhantuyakova Dawn Cochrane Gian Luca Negri Sandra Spencer Miko Taha Azad | 2024/3/4 |
Microrna-based compositions and methods used in disease treatment | 2024/1/25 | ||
Oncolytic rhabdovirus expressing IL12 | 2023/2/28 | ||
Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies | Nature communications | Taha Azad Reza Rezaei Ragunath Singaravelu Adrian Pelin Stephen Boulton | 2023/5/26 |
Oncolytic viruses as adjuvants | 2023/9/14 | ||
Modified vaccinia vectors | 2023/1/26 | ||
Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy | Pharmaceuticals | Nikolas T Martin Mathieu JF Crupi Zaid Taha Joanna Poutou Jack T Whelan | 2023/5/7 |
Successful adult vaccine drives must centre disability inclusion–Authors' reply | The Lancet | Sara Rotenberg Matthew Downer | 2023/7/29 |
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX | Frontiers in Immunology | Jack T Whelan Ragunath Singaravelu Fuan Wang Adrian Pelin Levi A Tamming | 2023 |
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus | Frontiers in Immunology | Zaid Taha Mathieu JF Crupi Nouf Alluqmani Faiha Fareez Kristy Ng | 2023/4/19 |
Recombinant polypeptides for programming extracellular vesicles | 2023/6/29 | ||
AT cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection | Molecular Therapy-Methods & Clinical Development | Stephen Boulton Joanna Poutou Rida Gill Nouf Alluqmani Xiaohong He | 2023/12/14 |
COVID-19 and other adult vaccines can drive global disease prevention | The Lancet | David B Agus Aurélia Nguyen John Bell | 2023/1/7 |
Deciphering aberrant STING pathway and exploring oncolytic viruses therapy in low grade serous ovarian carcinoma | Cancer Research | Almira Zhantuyakova Dawn Cochrane Gian Negri Sandra E Spencer Miko Taha Azad | 2023/4/4 |
Pathogen genomics in public health laboratories: successes, challenges, and lessons learned from California’s SARS-CoV-2 whole-genome sequencing initiative, California COVIDNet | Emily A Smith Kevin G Libuit Curtis J Kapsak Michelle R Scribner Sage M Wright | 2023/6/2 | |
Abstract A034: VV-iVP55: A Superior Vaccinia Virus Platform with Enhanced Oncolytic Potency and Immunogenicity | Cancer Immunology Research | Reza Rezaei Taha Azad Julia Petryk John C Bell | 2023/12/1 |
